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Introduction: Standard therapy for limited-stage small-cell lung 
cancer (L-SCLC) is concurrent chemotherapy and radiotherapy (RT) 
followed by prophylactic cranial radiotherapy. Although many con-
sider the standard RT regimen to be 45 Gy in 1.5 Gy twice-daily 
fractions, this has failed to gain widespread acceptance. We pooled 
data of patients assigned to receive daily RT of 70 Gy from three, 
consecutive prospective Cancer and Leukemia Group B L-SCLC 
cancer trials and report the results here.
Methods: All patients from consecutive Cancer and Leukemia Group 
B L-SCLC trials (39808, 30002, and 30206) using high-dosage daily 
RT with concurrent chemotherapy were included, and analyzed for 
toxicity, disease control, and survival. Overall survival (OS) and pro-
gression-free survival (PFS) were modeled using Cox proportional 
hazards models. Prognostic variables for OS-rate and PFS-rate were 
assessed using logistic regression model.
Results: Two hundred patients were included. The median follow-
up was 78 months. Grade 3 or greater esophagitis was 23%. The 
median OS for pooled population was 19.9 months (95% confi-
dence interval [CI]: 16.7–22.3), and 5-year OS rate was 20% 
(95% CI: 16–27%). The 2-year PFS was 26% (95% CI: 21–32%). 
Multivariate analysis found younger age (p = 0.02; hazard ratio 
[HR]: 1.023; 95% CI: 21-32), and female sex (p = 0.02; HR:0.69; 
95% CI: 0.50-0.94) independently associated with improved overall 
survival.
Conclusion: Two-Gy daily RT to a total dosage of 70 Gy was well 
tolerated with similar survival to 45 Gy (1.5 Gy twice-daily). This 
experience may aid practitioners decide whether high-dosage daily 
RT with platinum-based chemotherapy is appropriate outside of a 
clinical trial.
Key Words: Limited-stage small-cell lung cancer, Chemoradio-
therapy, Dosage-escalated radiotherapy.
(J Thorac Oncol. 2013;8: 1043-1049)
Small-cell lung cancer (SCLC) represents approximately 15% of all lung cancers.1 Patients with limited-stage (L) SCLC are 
treated with curative intent, consisting of concurrent multiagent 
chemotherapy and thoracic radiotherapy (TRT) followed by pro-
phylactic cranial radiotherapy. The median survival for patients 
treated with combined modality therapy ranges from 18 to 23 
months, with 5-year survival between 15% and 26%.2–4
Although radiotherapy improves survival for patients 
with L-SCLC,5 the ideal radiotherapy timing, dosage, and 
fractionation is unknown. In an attempt to provide improved 
intrathoracic tumor control, while not exceeding tolerance, 
a number of phase III studies have investigated concurrent 
chemotherapy, with twice daily3,4 and split-course twice-daily 
radiotherapy.2 Many consider the standard regimen to be 45 
Gy in 1.5 Gy twice-daily fractions delivered with concurrent 
and adjuvant cisplatin and etoposide because it was found to 
improve survival compared with 45 Gy in 1.8 Gy daily frac-
tions.4 However, twice-daily fractionation has failed to gain 
widespread acceptance.6 Many consider the control arm of 
Intergroup (INT) 0096 inadequate, the esophagitis associated 
with twice-daily radiotherapy too great, and twice daily radio-
therapy logistically difficult.
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A series of Cancer and Leukemia Group B (CALGB) studies 
have investigated high-dosage daily radiotherapy for L-SCLC as an 
alternative to twice-daily radiotherapy. CALGB 8837, investigating 
the maximal tolerated dosage of daily radiotherapy delivered with 
concurrent cisplatin/etoposide, found 70 Gy radiotherapy delivered 
in 2-Gy daily fractions tolerable.7 Subsequently, three studies8–10 
investi gated concurrent carboplatin (area under the curve = 5), 
etoposide (100 mg/m2), and 70 Gy radiotherapy for L-SCLC, after 
an initial two cycles of novel chemotherapy regimens. Although 
each CALGB study was relatively small, in combination these 
studies provide the largest prospective database of patients 
treated with high-dosage once-daily radiotherapy and concurrent 
platinum-based chemotherapy for L-SCLC. Given that many 
practitioners routinely choose a high-dosage regimen for their 
patients with L-SCLC, we pooled patients assigned to receive 70 
Gy radiotherapy on these three consecutive prospective CALGB 
L-SCLC trials and report their outcomes here.
PATIENTS AND METHODS
Eligibility
Eligibility criteria for CALGB 39808, 30002, and 
30206 have been previously published.8–10 In brief, patients 
with histologically or cytologically confirmed L-SCLC, 
defined as disease confined to the ipsilateral hemithorax, 
nodal disease limited to the ipsilateral hilum and/or bilateral 
TABLE 1.  Patient Characteristics
CALGB 30002 
(n = 63)
CALGB 30206 
(n =75)
CALGB 
39808 
(n = 62)
Overall  
(N = 200) p*
Sex 0.26
 Male 27 (43%) 42 (56%) 34 (55%) 103 (52%)
 Female 36 (57%) 33 (44%) 28 (45%) 97 (49%)
Age yr 0.59
 <60 25 (40%) 30 (40%) 29 (47%) 84 (42%)
 60–70 28 (44%) 29 (39%) 26 (42%) 83 (42%)
 >70 10 (16%) 16 (21%) 7 (11%) 33 (17%)
 Median 62 61 61.5 62
Race 0.19
 White 58 (92%) 73 (97%) 56 (32%) 187 (94%)
 Non-
White
5 (8%) 2 (3%) 6 (10%) 13 (7%)
Performance status 0.0246
 0 27 (43%) 49 (65%) 30 (48%) 106 (53%)
 1 33 (52%) 26 (35%) 29 (47%) 88 (44%)
 2 3 (5%) 0 (0%) 3 (5%) 6 (3%)
Weight loss 0.03
 None or 
<5%
48 (76%) 65 (87%) 39 (63%) 152 (76%)
 5% ≤ 
10%
10 (16%) 4 (4%) 13 (21%) 27 (14%)
 10% < 
20%
3 (5%) 4 (5%) 8 (13%) 15 (7%)
 ≥20% 2 (3%) 2 (3%) 2 (2%) 6 (3%)
Pleural effusion 0.002
 No 62 (98%) 66 (88%) 62 (100%) 190 (95%)
 Yes 1 (2%) 9 (12%) 0 (0%) 10 (5%)
aFisher’s exact test for balance among three studies.
CALGB, Cancer and Leukemia Group B.
TABLE 2.  Adverse Events during Induction Chemotherapy 
and Concurrent Chemoradiotherapy
Grade 3 Grade 4 Grade 5
Induction chemotherapy
Adverse event n % n % n %
Hemoglobin 10 5% 2 1% 1 1%
Leukocytes (total 
WBC)
9 (5%)  8 (4%)  0 (0%)
Lymphopenia 5 (3%)  0 (0%)  0 (0%)
Neutrophils/ 
granulocytes (ANC/ 
AGC)
23 (12%) 35 (18%)  0 (0%)
Platelets 7 4% 1 (1%)  0 (0%)
Transfusion: pRBCs 10 (5%)  0 (0%)  0 (0%)
Maximum 
hematologic AE
29 15% 36 18%  1 (1%)
Fatigue 9 (5%)  1 (1%)  0 (0%)
Anorexia 6 (3%)  0 (0%)  0 (0%)
Dehydration 6 (3%)  0 (0%)  0 (0%)
Diarrhea 17 (9%)  1 (1%)  0 (0%)
Esophagitis 1 (1%)  0 (0%)  0 (0%)
Nausea 9 (5%)  0 (0%)  0 (0%)
Febrile neutropenia 12 (6%)  2 (1%) 0 (0%)
Dyspnea 10 (5%)  4 (2%)  0 (0%)
Maximum 
nonhematologic AE
46 24% 6 3% 1 (1%)
Maximum overall AE 47 24% 38 19% 2 1%
Concurrent chemoradiotherapy
Hemoglobin 43 (22%)  5 (3%)  1 (1%)
Leukocytes (total 
WBC)
50 (25%)  45 (23%)  0 (0%)
Lymphopenia 19 (10%)  5 (3%)  0 (0%)
Neutrophils/ 
granulocytes (ANC/ 
AGC)
51 (26%) 108 (54%)  0 (0%)
Platelets 64 (32%)  21 (11%)  0 (0%)
Transfusion: pRBCs 21 (11%)  0 (0%)  0 (0%)
Maximum 
hematologic AE
47 (24%) 118 (59%)  1 (1%)
Fatigue 26 (13%)  1 (1%)  0 (0%)
Anorexia 20 (10%)  0 (0%)  0 (0%)
Dehydration 30 (15%)  0 (0%)  0 (0%)
Diarrhea 20 (10%)  1 (1%)  0 (0%)
Esophagitis  41 (21%)  4 (2%)  0 (0%)
Nausea 21 (11%)  0 (0%)  0 (0%)
Febrile neutropenia 32 (16%)  5 (3%)  1 (1%)
Dyspnea 10 (5%)  4 (2%)  0 (0%)
Maximum 
nonhematologic AE
100 (50%)  21 (11%)  2 (1%)
Maximum overall AE 57 (29%) 121 (61%) 3 (2%)
AE, adverse event; ANC, absolute neutrophil count; AGC, absolute granulocyte 
count; RBCs, red blood corpuscles; WBC, white blood corpuscle.
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mediastinum, Eastern Cooperative Oncology Group perfor-
mance status (PS) of 0 to 1, and normal organ and marrow 
function were eligible. All patients included in this analy-
sis started therapy with the intent to deliver two cycles of 
systemic therapy followed by concurrent chemotherapy and 
radiotherapy to 70 Gy.
Chemotherapy Treatment Plan
The treatment plan for these studies consisted of two 
cycles of induction chemotherapy followed by concurrent 
chemotherapy and radiation therapy (RT). Induction chemo-
therapy on CALGB 39808 consisted of topotecan 1 mg/m2 
days 1 to 5 and 22 to 26, and paclitaxel 175 mg/m2 days 1 
and 22 with granulocyte colony-stimulating factor (G-CSF) 5 
microg/kg days 6 and 27. CALGB 30002 included induction 
etoposide 160 mg/m2 orally days 5 to 7 and 26 to 28, paclitaxel 
110 mg/m2 days 1 and 22, and topotecan 1.5 mg/m2 days 2 to 
4 and 23 to 26. CALGB 30206 included induction cisplatin 
30 mg/m2 and irinotecan 65 mg/m2 both on days1, 8, 22, 29. 
For all three trials, radiotherapy started on day 43 and was 
administered concurrently with carboplatin (area under the 
curve of 5 using the Calvert equation) on days 43, 64, 85, and 
etoposide 100 mg/m2 on days 43 to 45, 64 to 66, and 85 to 87. 
Details of premedication, dosage modifications, and chemo-
therapy treatment delays have been published previously.
Radiation Treatment Plan
After induction chemotherapy, all patients receiving 
RT underwent computed tomography (CT)-based radiation 
treatment planning. Gross tumor volumes of the primary and 
pathologically involved lymph nodes were contoured based 
on the postchemotherapy volume. For the first phase of treat-
ment, the primary tumor and pathologically involved adenop-
athy (those with a necrotic center, biopsy proven, positron 
emission tomography-avid, or measuring > 1 cm in short-axis 
diameter) were contoured on each slice of the planning CT as 
GTV1. Clinical target volume 1 (CTV-1) included GTV-1, the 
ipsilateral hilum, and lymph node stations 3, 4R, 4L, and 7. 
Stations 5 and 6 were included for left lung primary tumors. 
Planning target volume 1 (PTV-1) included CTV-1 with a 
1-cm margin. CTV 2 included only GTV-1. PTV-2 included 
CTV-2 with a 1-cm margin.
Initially two-dimensional and three-dimensional con-
formal techniques were allowed. Intensity-modulated RT was 
not permitted. Radiation beam configurations were chosen to 
minimize dosage to the heart and lungs. No corrections were 
made for tissue heterogeneity. The maximum dosage to the 
spinal cord was limited to 50 Gy. Initially, 2-Gy daily fractions 
were delivered to PTV-1 to 44 Gy. Subsequently, an additional 
26 Gy in 2-Gy fractions was delivered to PTV-2. The cumula-
tive dosage to gross disease was 70 Gy. Normal tissue guide-
lines included limiting 50% of the total lung volume to less 
than 25 Gy. The entire heart volume was to receive less than 
25 Gy. Treatment was only delayed for grade 4 esophagitis or 
grade 4 neutropenia with fever. Prophylactic cranial irradia-
tion (PCI) was offered to patients with a complete response 
(CR) or a very good partial response (PR) as determined by 
restaging studies after the completion of all chemotherapy and 
RT. The dosage of PCI was left to the discretion of the treat-
ing radiation oncologist, with suggested schedules including 
36 Gy (2 Gy/fraction), 25 Gy (2.5 Gy/fraction), and 24 Gy (3 
Gy/fraction).
Follow-Up and Response Measurement
After the completion of treatment, patients were evalu-
ated every 3 months for 2 years, then every 6 months for 3 
years, and subsequently, at yearly intervals. At each evalua-
tion, patients underwent and physical examination with his-
tory, complete blood count, and chest radiography. Chest CT 
scans were performed every 6 months for 2 years and then 
yearly for 2 additional years.
Criteria for a CR were the disappearance of all disease. 
A PR was defined as more than 50% reduction in the sum of 
the longest diameters of all measured target lesions, without 
the development of new lesions, or enlargement of any existing 
lesions. Stable disease was defined as a less than 50% reduction 
TABLE 3.  Response Rates after Induction Chemotherapy 
and Chemoradiotherapy
CALGB 
30002  
n = 63 (%)
CALGB 
30206  
n = 75 (%)
CALGB 
39808  
n = 62 (%)
Total  
N = 200 p**
Induction chemotherapy
 CR 5(8) 5(7) 1(2) 11(6) 0.63
 PR 37(59) 48(64) 47(76) 132(66)
 Stable 13(21) 13(17) 12(19) 38(19)
 PD 1(2) 1(1) 1(2) 3(2)
 Unevaluable 7(11) 8(11) 1(2) 16(8)
 Overall response 
rate
42(67) 53(71) 48(77) 143(72) 0.86
Chemoradiotherapy
 CR 27(43) 28(37) 27(44) 82(41) 0.82
 PR 25(40) 38(51) 30(48) 93(47)
 Stable 6(10) 6(8) 3(5) 15(8)
 PD 2(3) 1(1) 1(2) 4(2)
 Unevaluable 3(5) 2(3) 1(2) 6(3)
 Overall response 
rate
52(83) 66(88) 57(92) 175(88) 0.45
**Fisher’s exact test, excluding unevaluable patients.
CR, complete response; PR, partial response; PD, progressive disease;  CALGB, 
Cancer and Leukemia Group B.
TABLE 4.  Patterns of First Progression (Online Only)
Relapse Type
CALGB  
30002 
(%)
CALGB  
30206 
(%)
CALGB  
39808 
(%) Total (%)
Distant only 18 (29) 18 (24) 21 (34) 57 (29)
Local only 8 (13) 9 (12) 9 (15) 26 (13)
Local and distant 7 (11) 14 (19) 9 (15) 30 (15)
No relapse 30 (48) 34 (45) 23 (37) 87 (44)
Total 63 75 62 200
CALGB, Cancer and Leukemia Group B.
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or less than 25% increase in the sum of the longest diameters 
of all measured target lesions compared with the size present at 
entry in the study, and without the development of new lesions. 
Objective progression or relapse was defined as the appearance 
of new lesions or sites of disease, or an increase in the sum of 
the longest diameters of all measured target lesions by more than 
30% compared with the size referenced at study registration, or 
at the time of maximum regression.
Statistical Analysis Method
CALGB statisticians performed all statistical analyses. 
Kaplan–Meier curves were used to describe overall survival (OS) 
and progression-free survival (PFS) time and the relationship 
between the survival time and response. Survival time was defined 
as the time between the initiation of induction chemotherapy 
and death. PFS was computed as the time between initiation of 
induction chemotherapy and disease progression or death. OS 
and PFS are modeled using Cox proportional hazards models. 
Prognostic variables for OS-rate and PFS-rate were assessed using 
logistic regression model. Fisher’s exact tests, where appropriate, 
were performed for assessing statistical significance in frequency 
tables. All analyses were conducted on the entire study population, 
regardless of whether they received the planned 70 Gy RT or not. 
The reported p values are two-sided and unadjusted for multiple 
comparisons. p values of 0.05 were taken as being statistically 
FIGURE1. A, Overall survival by study. B, Progression-free survival by study. C, Overall survival for all patients. D, Progression-
free survival for all patients. CALGB, Cancer and Leukemia Group B.
TABLE 5.  Survival Status by Study (N = 200)
CALGB  
39808  
(n = 62)
CALGB  
30002  
(n = 63)
CALGB  
30206  
(n = 75)
All Three  
Studies  
(N = 200)
No. of deaths 52 50 63 165
No. of progression 52 50 66 168
Median OS (mo) 
(95%CI)
21.9 
(15.2,32.0)
20.3  
(16.2, 23.5)
18.1  
(15.8, 22.9)
19.9  
(16.7, 22.3)
Median PFS (mo)  
(95%CI)
13.2  
(9.9,19.9)
11.6  
(9.3, 14.8)
12.6 (9.4,14.7) 12.3  
(10.8, 13.6)
2-year OS 45% 
(34%,59%)
33% 
(24%,47%)
31% 
(22%,43%)
37%  
(31%,44%)
2-year PFS 29% 
(20%,43%)
25% 
(17%,39%)
21% 
(14%,33%)
26%  
(21%,32%)
5-year OS 19% 
(12%,32%)
23%  
(15%, 37%)
17% 
(10%,28%)
20%  
(16%,27%)
OS, overall survival; PFS, progression-free survival; CI, confidence interval; 
CALGB, Cancer and Leukemia Group B.
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significant. All analyses were performed using SAS (Version 9.2; 
SAS Institute, Cary, North Carolina).
RESULTS
The first patient for CALGB 39808 was accrued in June 
1999, for CALGB 30002 in October 2001, and for CALGB 
30206 in January 2004. The total study population of 200 
patients comprised 63 patients from CALGB 30002, 75 
patients from CALGB 30206, and 62 patients from 39808, 
respectively. Patient and tumor characteristics are listed in 
Table 1. The median age was 62 years, most patients had mini-
mal weight loss (76%), and most patients were men (51.5%). 
Characteristics were well balanced between the trials with the 
exception of improved PS, less weight loss, and higher rates 
of baseline pleural effusion in CALGB 30206. The median 
follow-up was 78 months.
The mean and median radiation dosage delivered to 
all patients was 68.9 and 70 Gy, respectively. RT was deliv-
ered per protocol in 93 patients (46.5%), of which 32 patients 
(16%) received radiation with a minor deviation, and 32 
patients (16%) had a major deviation. Five patients (2.5%) did 
not have radiation data available for review.
Toxicity of Induction Chemotherapy
The initial two cycles of chemotherapy were tolerated 
with the expected toxicities and responses. Toxicities are listed in 
Table 2. Hematologic adverse events (AEs) predominated. Grade 
3 to 4 neutropenia was the most common AE at 30%. Two grade 5 
AEs were attributed to induction chemotherapy. The most common 
nonhematologic grade 3 to 4 AE was diarrhea (10%). Response to 
induction chemotherapy is shown in Table 3. The overall response 
rates were similar for all studies (CALGB 39808 = 77%, CALGB 
30002 = 67%, CALGB 30206 = 71%, 72% for pooled population; 
p = 0.86) as were the rates of stable disease and progression. Of 
the 200 patients who participated in these three trials, 179 (90%) 
proceeded to TRT after induction chemotherapy.
Toxicity of Concurrent Phase
Concurrent carboplatin, etoposide, and TRT were toler-
ated with the expected side effects (Table 2). The most com-
mon grade 3 to 4 toxicities were hematologic. This included 
grade 3 to 4 neutropenia in 80%, grade 3 to 4 leukopenia in 
48%, grade 3 to 4 thrombocytopenia in 43%, and grade 3 to 
4 anemia in 25%. Nineteen percent experienced febrile neu-
tropenia. The most common nonhematologic grade 3 to 4 tox-
icities were esophagitis, experienced by 23% of patients, and 
dehydration experienced by 15% of the patients.
Response to complete Treatment Package
After the completion of induction chemotherapy and 
concurrent chemotherapy and TRT, the overall response rate 
TABLE 6.  Univariate Analyses (Online Only)
Variable
Survival Distribution
2-Year Overall 
Survival
No. of 
Patients
Median 
(mo)a
Hazard 
Ratiob
Wald  
pc
Rate 
(%)d
Wald  
pe
Age, yr 200 1.027 0.0033 0.0181
 ≤59 84 21.0 44.1
 60–70 83 17.1 37.4
 >70 33 15.5 12.1
Sex 0.682 0.0167 0.0084
 Male 103 16.7 28.2
 Female 97 22.9 45.4
Performance status 1.296 0.1023 0.1061
 0 106 20.6 41.5
 1 and 2 94 17.0 30.9
Weight loss 1.211 0.2961 0.1646
 <5% 152 19.9 38.9
 ≥5% 48 19.9 29.2
aMedian survivals are taken from Kaplan–Meier plots.
bHazard ratios are estimated from proportional hazards models.
cp values are from proportional hazards model using the Wald test.
dTwo-year survival rates are taken from Kaplan–Meier plots.
ep values are from logistic regression analysis.
FIGURE 2. A, OS by response to induction chemotherapy.  
B, PFS by response to induction chemotherapy. CALGB, 
Cancer and Leukemia Group B; OS, overall survival; PFS, 
progression-free survival; CR, complete response; PR, partial 
response; PD, progressive disease.
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was 88%, similar to that of the individual studies (CALGB 
39808 = 92%, CALGB 30002 = 83%, CALGB 30206 = 88%; 
p = 0.45) (Table 3).
Patterns of Progression
Patterns of first progression are reported in Table 4. After 
the completion of therapy, 26 patients experienced locore-
gional progression only, 30 patients experienced locoregional 
progression and distant progression, and 57 experienced dis-
tant progression only. The crude locoregional relapse rate at 
first progression was 28%.
Survival
There was no difference in OS or PFS between stud-
ies (Fig. 1). The median OS for pooled population was 19.9 
months (95% confidence interval, [CI]: 16.7–22.3), which 
was similar to each trial individually (Table 5). The 2-year 
and 5-year OS rates were 37% (95% CI: 31–44%) and 21% 
(95% CI: 16–27%), respectively. The median and 2-year PFS 
was 12.3 months (95% CI: 10.8–13.6) and 26% (95% CI: 21–
33%), respectively.
Patients with either a CR, or a PR to induction chemo-
therapy were compared with those with stable disease or pro-
gression, to determine whether this would predict for OS or 
PFS. Responders had longer PFS (p = 0.16) and OS (p = 0.18), 
but it was not statistically significant. (Fig. 2).
Improved OS was associated with younger age (<60) 
(p = 0.003) and the female sex (p = 0.02) in univariate analy-
ses (Table 6). Multivariate analysis confirmed that younger 
age (p = 0.02; hazard ratio: 1.02; 95% CI: 1.00, 1.04), and 
female sex (p = 0.02); hazard ratio: 0.69; 95% CI: 0.50–0.94) 
were independently associated with improved OS, when 
adjusted for PS and weight loss (Table 7). Multivariate analy-
sis for PFS identified improved PFS in women (p = 0.02) and 
in those with less than 5% weight loss (p = 0.07). Age was not 
significantly associated with improved PFS.
DISCUSSION
In this analysis we report the outcomes of 200 consecutive 
patients treated on three CALGB protocols who received 
two cycles of induction therapy followed by 70 Gy daily 
radiotherapy, administered concurrently with platinum-based 
chemotherapy for L-SCLC, followed by PCI, in responding 
patients. These patients treated with high-dosage daily 
radiotherapy had rates of grade 3 or greater (3+) esophagitis 
of 23%, median survival of 19.9 months, and 5-year survival 
of 21%. The survival was similar to those reported for patients 
on the two phase III trials with twice-daily radiotherapy. On 
INT 0096 patients had 32% grade 3+ esophagitis, 23-month 
median survival, and 26% 5-year survival. In North Central 
Cancer Treatment Group (NCCTG) 89-20-52, patients had a 
12% rate of 3+ esophagitis, 20.6-month median survival, and a 
22% 5-year survival2,4 The esophagitis rates seemed less with 
daily fractionation or split-course twice-daily fractionation.
Data on large numbers of L-SCLC patients treated with 
high-dosage daily radiotherapy are scarce and limited to sin-
gle-institution series. Although select retrospective reports11–13 
have supported the use of high-dosage radiotherapy, the data 
presented here represent the largest series to date using this 
approach. Patients in this series were treated with a standard-
ized approach at multiple institutions in prospective phase II 
studies, with central data monitoring and collection, and as 
central radiotherapy quality assurance. Therefore, the resulting 
data more accurately describe the results of concurrent che-
motherapy and high-dosage daily radiotherapy. The limitations 
of this study are that all patients were treated with two cycles 
of chemotherapy before chemoradiotherapy. Some patients 
progressed during induction therapy, and thus, did not receive 
the potential benefits of radiotherapy. Furthermore, there are 
limitations in comparing the results of phase II and phase III 
trials, particularly, when the studies are conducted in differ-
ent eras with the potential to select somewhat different patient 
populations.
Although accelerated radiotherapy delivered in twice-
daily 1.5-Gy fractions to a total dosage of 45 Gy was shown 
to improve survival compared with 45-Gy radiotherapy 
delivered in 1.8-Gy daily fractions, this has not been widely 
adopted. The reasons for the lack of widespread adoption are 
likely related to the logistical difficulties of delivering twice-
daily therapy and the 32% grade 3 to 4 esophagitis rate. On 
the basis of the extrapolation from phase I data7 and radia-
tion dose–response data,14 many have delivered radiotherapy 
in daily fractionated radiotherapy to dosages more than 50 
Gy.11,12 However, these single-institution series are hindered 
by their retrospective nature and small size.
In our pooled analysis we found that 2-Gy daily 
radiotherapy to a total dosage of 70 Gy was relatively well 
tolerated. The grade 3+ esophagitis rate was 23% compared 
with the 32% grade 3+ esophagitis rate seen in INT 0096. 
Both these studies used similar radiation techniques without 
intentional sparing of the esophagus. However, Radiation 
Therapy Oncology Group 0239 reported a lower grade 3+ 
esophagitis rate (18%) delivering RT through an accelerated 
concomitant boost technique.15 However, this study was 
conducted in an era of more advanced radiation planning 
techniques with guidelines limiting the amount of esophagus 
that could receive high dosages of RT. With further advanced 
radiotherapy planning techniques and potentially the use 
of limited radiation fields, the rates of esophagitis for all 
TABLE 7.  Multivariate Analysis (Online Only)
Parameter p HR 95% CI
Overall survival
Age, yr 0.0165 1.023 (1.004–1.042)
Sex 0.0192 0.685 (0.499–0.940)
Performance status 0.2004 1.231 (0.896–1.692)
Weight loss 0.6893 1.078 (0.746–1.556)
Progression-free survival
Age, yr 0.1509 1.013 (0.995–1.032)
Sex 0.0217 0.693 (0.507–0.948)
Performance status 0.3998 1.145 (0.835–1.569)
Weight loss 0.0731 1.394 (0.969–2.004)
HR, hazard ratio; CI, confidence interval.
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treatment delivery schemes should be further reduced. We 
also found that rates of grade 3+ pulmonary toxicity was low 
and will present these results and predictors of toxicity in 
another article.
The favorable survival and locoregional control in 
this series was obtained, even though a carboplatin-based 
regimen was given during radiotherapy, and the initiation of 
radiotherapy was delayed until the third cycle of chemotherapy. 
The substitution of carboplatin for cisplatin in SCLC remains 
controversial, but was adopted in the CALGB phase II studies, 
given the preference of many participating communities 
of oncologists for the drug. That said, cisplatin remains 
the standard of care outside a clinical trial, particularly, 
when treating potentially curable patients with limited-
stage disease. The optimal timing of initiating radiotherapy, 
likewise, remains an area of controversy.3,16 Randomized 
studies and meta-analyses17,18 have shown a benefit for earlier 
radiotherapy. It is possible that on the basis of these studies, the 
results of the present study would have been more favorable if 
the radiotherapy component was started earlier than with the 
cycle 3 of chemotherapy.
Locoregional control in this series was 77%, which 
compared favorably with the 64% seen in INT 0096, and 
similar to that seen in RTOG 0239. Dose–response data of 
daily fractionated chemoradiotherapy demonstrate a dose–
response relationship suggesting that dosages more than 50 
Gy are associated with improved locoregional control.14,19,20 
An unanswered question is whether even higher dosages of 
radiotherapy would be associated with improved locoregional 
control. We selected 70 Gy as it was the highest dosage inves-
tigated in the underlying phase I study.7 However, maximum 
tolerated dosage was not reached in that study. Others have 
reported21 on the potential relationship between biologically 
effective dosage of RT and 5-year survival, suggesting poten-
tial benefits for the higher dosage regimens used in CALGB 
30610. Whether even higher dosages can improve the thera-
peutic ratio, particularly in an era of advanced imaging and 
treatment delivery, is fertile ground for future research.
Whether 70 Gy daily RT is better than the current stan-
dard of care is an open question, which is currently addressed 
in an ongoing intergroup study (CALGB 30610). A separate 
phase III trial in the United Kingdom and Canada is compar-
ing 66-Gy daily RT with 45-Gy twice-daily RT. Until those 
trials are completed and their data are mature, the CALGB 
phase II experience can help practitioners decide whether the 
high-dosage daily RT delivered concurrently with platinum-
based chemotherapy is appropriate outside a clinical trial, for 
patients with L-SCLC.
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